AI-extracted from the 10-Q filed 2026-08-11 — Q2 FY2026 (quarter ended July 5, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revvity delivered $729.7M in Q2 revenue (+1% YoY), with Diagnostics segment surging 5% driven by Reproductive Health, though Life Sciences declined 2% on Software weakness.
Biggest Revenue Drivers
Diagnostics$371.0M+5% YoY
Reproductive Health revenue increased $20.7M, partially offset by $4.1M decline in Immunodiagnostics.
Life Sciences$358.7M-2% YoY
Software revenue decreased $10.2M, partially offset by $3.0M increase in Life Sciences Solutions revenue.
Biggest Revenue Drivers
Total revenue: $729.7M+1% YoY
Diagnostics$371.0M+5% YoY
Reproductive Health revenue increased $20.7M, partially offset by $4.1M decline in Immunodiagnostics.
Life Sciences$358.7M-2% YoY
Software revenue decreased $10.2M, partially offset by $3.0M increase in Life Sciences Solutions revenue.
Largest Expense Items
Selling, general and administrative expenses$278.6M+12% YoY
Restructuring charges increased to $35.5M (from $11.2M) and digital investments drove increases, partially offset by lower acquisition costs.
Cost of revenue$312.8M-5% YoY
Tariff refunds of $16.2M and favorable product mix shift increased gross margin 260 basis points to 57.1%.
Research and development expenses$49.0M-8% YoY
Decrease driven by cost containment initiatives.
Margins: Gross margin expanded 260 basis points to 57.1%, primarily from tariff refunds and product mix shift. Operating margin declined slightly to 12.2% from 12.6% due to restructuring charges and digital investments offsetting gross margin gains.
Watch Items from the Filing
Restructuring costs surged to $35.5M in Q2 from $11.2M YoY; 5% workforce reduction planned across six-month period affecting cost structure.
Software revenue declined $10.2M YoY in Q2; Life Sciences segment facing margin pressure from strategic software investments.
Company divesting China Immunodiagnostics business (≈6% of FY2025 revenue) by end of 2027; expected to close subject to regulatory approvals.
Tariff refunds totaling $16.2M received through July 5, 2026 (applied for $20.2M); timing and additional recoveries remain uncertain.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Vounatsos MichelReporting ownerGrant or award · May 7, 2026
Congress trading in RVTY
16 transactions in RVTY reported by 4 members of Congress under the STOCK Act, most recent trade Sep 9, 2026. Reported transactions, not recommendations.
About REVVITY, INC. (RVTY): stock profile, AI score and financials
REVVITY, INC. (RVTY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RVTY at 58.0/100 on a composite quality score built from its SEC filings, placing it at rank #1,048 of 2,925 stocks — the top half of the AI-ranked universe. RVTY scores in the top quartile across earnings quality (87.7). Areas of concern include institutional flow (18.6) and revenue growth (37.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), REVVITY, INC. reports quarterly revenue of $729.7M, net income of $51.8M, an operating margin of 12.2%. Top institutional holders of RVTY by reported 13-F value include T. Rowe Price Investment Management, Jupiter Topco, EdgePoint Investment Group, based on the most recent SEC filings. RVTY trades on the NYSE exchange and files with the SEC under CIK 31791. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RVTY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for REVVITY, INC. directly from SEC EDGAR.